SEARCH

SEARCH BY CITATION

References

  • Adams J. R., Van Netten H., Schulzer M. et al. (2005) PET in LRRK2 mutations: comparison to sporadic Parkinson’s disease and evidence for presymptomatic compensation. Brain 128, 27772785.
  • Bibbiani F., Oh J. D., Kielaite A., Collins M. A., Smith C. and Chase T. N. (2005) Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD. Exp. Neurol. 192, 7378.
  • Breese G. R. and Traylor T. D. (1971) Depletion of brain noradrenaline and dopamine by 6-hydroxydopamine. Br. J. Pharmacol. 42, 8899.
  • Carta M., Carlsson T., Kirik D. and Björklund A. (2007) Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain 130, 18191833.
  • Cenci M. A. and Lundblad M. (2006) Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia. J. Neurochem. 99:381392 Review.
  • Deutsch H. M., Skolnick P., Rafferty M., Rice M. F., Janowski A. J. and Paul S. M. (1996) Synthesis and pharmacology of potential cocaine antagonists.2. Structure-activity relationship studies of aromatic ring-substituted methylphenidate analogs. J. Med. Chem. 39, 12011209.
  • Doudet D. J., Jivan S., Ruth T. J. and Holden J. E. (2002) Density and affinity of the dopamine D2 receptors in aged symptomatic and asymptomatic MPTP-treated monkeys: PET studies with [11C]raclopride. Synapse 44, 198202.
  • De La Fuente-Fernández R., Lim A. S., Sossi V., Holden J. E., Calne D. B., Ruth T. J. and Stoessl A. J. (2001a) Apomorphine-induced changes in synaptic dopamine levels: positron emission tomography evidence for presynaptic inhibition. J. Cereb. Blood Flow Metab. 21, 11511159.
  • De La Fuente-Fernández R., Lu J. Q., Sossi V., Jivan S., Schulzer M., Holden J. E., Lee C. S., Ruth T. J., Calne D. B. and Stoessl A. J. (2001b) Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson’s disease: PET evidence of increased dopamine turnover. Ann. Neurol. 49, 298303.
  • De La Fuente-Fernández R., Schulzer M., Mak E., Calne D. B. and Stoessl A. J. (2004a) Presynaptic mechanisms of motor fluctuations in Parkinson’s disease: a probabilistic model. Brain 127, 888899.
  • De La Fuente-Fernández R., Sossi V., Huang Z., Furtado S., Lu J. Q., Calne D. B., Ruth T. J. and Stoessl A. J. (2004b) Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson’s disease: implications for dyskinesias. Brain 127, 27472754.
  • Gunn R. N., Lammertsma A. A., Hume S. P. and Cunningham V. J. (1997) Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage 6, 279287.
  • Innis R. B., Cunningham V. J., Delforge J. et al. (2007) Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J. Cereb. Blood Flow Metab. 27, 15331539.
  • Kelly P. H. and Iversen S. D. (1976) Selective 6-OHDA-induced destruction of mesolimbic dopamine neurons: abolition of psychostimulant-induced locomotor activity in rats. Eur. J. Pharmacol. 40, 4556.
  • Kim J. S., Lee J. S., Im K. C., Kim S. J., Kim S. Y., Lee D. S. and Moon D. H. (2007) Performance measurement of the microPET focus 120 scanner. J. Nucl. Med. 48, 15271535.
  • Lammertsma A. A. and Hume S. P. (1996) Simplified reference tissue model for PET receptor studies. Neuroimage 4, 153158.
  • De Lau L. M. and Breteler M. M. (2006) Epidemiology of Parkinson’s disease. Lancet Neurol. 5, 525535.
  • Lee C. S., Samii A., Sossi V. et al. (2000) In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson’s disease. Ann. Neurol. 47, 493503.
  • Lee J., Zhu W. M., Stanic D. et al. (2008) Sprouting of dopamine terminals and altered dopamine release and uptake in Parkinsonian dyskinaesia. Brain 131, 15741587.
  • Masuo Y., Pélaprat D., Scherman D. and Rostène W. (1990) [3H]Dihydrotetrabenazine, a new marker for the visualization of dopaminergic denervation in the rat striatum. Neurosci. Lett. 114, 4550.
  • Meltzer P. M., Wang P., Blundell P. and Madras B. K. (2003) Synthesis and evaluation of dopamine and serotonin transporter inhibition by oxacyclic and carbacyclic analogues of methylphenidate. J. Med. Chem. 46, 15381545.
  • Nikolaus S., Larisch R., Beu M., Forutan F., Vosberg H. and Müller-Gärtner H. W. (2002) Bilateral increase in striatal dopamine D2 receptor density in the 6-hydroxydopamine-lesioned rat: a serial in vivo investigation with small animal PET. Eur. J. Nucl. Med. Mol. Imaging 30, 390395.
  • Parkinson’s Study Group (2002) Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson’s disease progression. JAMA 287(13), 16531661.
  • Parkinson’s Study Group (2004) Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch. Neurol. 61, 10441053.
  • Patel J., Mooslehner K. A., Chan P. M., Emson P. C. and Stamford J. A. (2003) Presynaptic control of striatal dopamine neurotransmission in adult vesicular monoamine transporter 2 (VMAT2) mutant mice. J. Neurochem. 85, 898910.
  • Pavese N., Evans A. H., Tai Y. F., Hotton G., Brooks D. J., Lees A. J. and Piccini P. (2006) Clinical correlates of levodopa-induced dopamine release in Parkinson disease: a PET study. Neurology 67, 16121617.
  • Paxinos G. and Watson C. (1998) The Rat Brain in Stereotaxic Coordinates. Academic Press, San Diego, CA.
  • Piccini P., Pavese N. and Brooks D. J. (2003) Endogenous dopamine release after pharmacological challenges in Parkinson’s disease. Ann. Neurol. 53, 647653.
  • Rinne J. O., Laihinen A., Ruottinen H., Ruotsalainen U., Någren K., Lehikoinen P., Oikonen V. and Rinne U. K. (1995) Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson’s disease: a PET study with [11C]raclopride. J. Neurol. Sci. 132, 156161.
  • Schiffer W. K., Alexoff D. L., Shea C., Logan J. and Dewey S. L. (2005) Development of a simultaneous PET/microdialysis method to identify the optimal dose of 11C-raclopride for small animal imaging. J. Neurosci. Methods 144, 2534.
  • Sossi V., De La Fuente-Fernández R., Holden J. E., Doudet D. J., McKenzie J., Stoessl A. J. and Ruth T. J. (2002) Increase in dopamine turnover occurs early in Parkinson’s disease: evidence from a new modeling approach to PET 18F-fluorodopa data. J. Cereb. Blood Flow Metab. 22, 232239.
  • Sossi V., De La Fuente-Fernández R., Schulzer M., Troiano A. R., Ruth T. J. and Stoessl A. J. (2007a) Dopamine transporter relation to dopamine turnover in Parkinson’s disease: a positron emission tomography study. Ann. Neurol. 62, 468474.
  • Sossi V., Holden J. E., Topping G. J., Camborde M. L., Kornelsen R., McCormick S., Greene J., Studenov A. R., Ruth T. J. and Doudet D. J. (2007b) In vivo measurement of density and affinity of the monoamine vesicular transporter in a unilateral 6-hydroxydopamine rat model of PD. Cereb Blood Flow Metab. 27, 14071415.
  • Strome E. M., Cepeda I. L., Sossi V. and Doudet D. J. (2006) Evaluation of the integrity of the dopamine system in a rodent model of Parkinson’s disease: small animal positron emission tomography compared to behavioral assessment and autoradiography. Mol. Imaging Biol. 8, 292299.
  • Troiano A., De La Fuente-Fernandez R., Sossi V., Schulzer M., Ruth T. J. and Stoessl A. J. (2009) Positron emission tomography demonstrates reduced dopamine transporter expression in PD patients with dyskinesias. Neurology, [Epub ahead of print] doi:DOI: 10.1212/01.wnl.0000338631.73211.56.
  • Whishaw I. Q., Gorn B., Tran-Nguyen L. T. L., Casteneda E., Miklyaeva E. I. and Pellis S. M. (1994) Making two movements at once: impairments of movement, posture, and their integration underlie the adult skilled reaching deficit of neonatally dopamine-depleted rats. Behav. Brain Res. 61, 6577.
  • Zigmond M. J., Stricker E. M. and Berger T. W. (1987) Parkinsonism: insights from animal. models utilizing neurotoxic agents, in Animal Models of Dementia (CoyleJ. Y., ed.), pp. 138. Alan R. Liss, New York.
  • Zigmond M. J., Abercrombie E. D., Berger T. W., Grace A. A. and Stricker E. M. (1990) Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci. 13, 290295.